Akebia Therapeutics, Inc. (AKBA)
0.9188
+0.04
(+4.58%)
USD |
NASDAQ |
Aug 31, 16:00
0.9189
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Cash from Operations (TTM) : 41.55M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 41.55M |
| March 31, 2026 | 60.37M |
| December 31, 2025 | 67.99M |
| September 30, 2025 | 32.40M |
| June 30, 2025 | -2.403M |
| March 31, 2025 | -34.81M |
| December 31, 2024 | -40.66M |
| September 30, 2024 | -38.50M |
| June 30, 2024 | -38.97M |
| March 31, 2024 | -25.28M |
| December 31, 2023 | -23.38M |
| September 30, 2023 | -75.76M |
| June 30, 2023 | -34.78M |
| March 31, 2023 | -69.07M |
| December 31, 2022 | -73.15M |
| September 30, 2022 | -81.28M |
| June 30, 2022 | -171.36M |
| March 31, 2022 | -203.84M |
| December 31, 2021 | -252.96M |
| September 30, 2021 | -220.94M |
| June 30, 2021 | -191.91M |
| March 31, 2021 | -91.54M |
| December 31, 2020 | -110.39M |
| September 30, 2020 | -171.74M |
| June 30, 2020 | -133.52M |
| Date | Value |
|---|---|
| March 31, 2020 | -209.10M |
| December 31, 2019 | -257.44M |
| September 30, 2019 | -239.00M |
| June 30, 2019 | -262.46M |
| March 31, 2019 | -215.09M |
| December 31, 2018 | -97.49M |
| September 30, 2018 | -40.17M |
| June 30, 2018 | -82.33M |
| March 31, 2018 | -66.96M |
| December 31, 2017 | -56.16M |
| September 30, 2017 | 55.89M |
| June 30, 2017 | 82.26M |
| March 31, 2017 | 30.94M |
| December 31, 2016 | 57.91M |
| September 30, 2016 | -60.68M |
| June 30, 2016 | -41.46M |
| March 31, 2016 | -26.63M |
| December 31, 2015 | -52.41M |
| September 30, 2015 | -38.70M |
| June 30, 2015 | -35.27M |
| March 31, 2015 | -29.82M |
| December 31, 2014 | -27.48M |
| September 30, 2014 | -23.19M |
| June 30, 2014 | -20.52M |
| March 31, 2014 | -15.81M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Emergent BioSolutions, Inc. | 97.70M |
| Exelixis, Inc. | 1.183B |
| ADMA Biologics, Inc. | 136.72M |
| Arcutis Biotherapeutics, Inc. | 39.31M |
| Relay Therapeutics, Inc. | -212.20M |